⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7657126 | 0.64 | CYP2A6 (0.32) | — | |
| SCHEMBL7011802 | 0.62 | — | — | |
| SCHEMBL10560214 | 0.60 | ASIC3 (0.33) | — | |
| SCHEMBL3279288 | 0.60 | EGFR (0.34) | — | |
| SCHEMBL7057830 | 0.60 | — | — | |
| SCHEMBL1785837 | 0.59 | MEN1 (0.40) | — | |
| SCHEMBL5922203 | 0.58 | — | — | |
| SCHEMBL88833 | 0.58 | — | — | |
| SCHEMBL5894227 | 0.57 | CHEK1 (0.35) | — | |
| SCHEMBL14989378 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605144-B2 | Enzyme catalyzed therapeutic compounds | CELMED ONCOLOGY (USA), INC. (CA) | 2009-10-20 | — | — | US | disclosed |
| EP-1200455-B1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | CELMED ONCOLOGY USA INC (CA) | 2009-04-22 | — | — | EP | disclosed |
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | CELMED ONCOLOGY (USA), INC. | 2009-03-12 | — | — | US | disclosed |
| US-7462605-B2 | Phosphoramidate compounds and methods of use | CELMED ONCOLOGY (USA), INC. (CA) | 2008-12-09 | — | — | US | disclosed |
| US-20070213307-A1 | Methods to treat autoimmune and inflammatory conditions | CELMED ONCOLOGY (USA), INC. | 2007-09-13 | — | — | US | disclosed |
| US-7138388-B2 | Methods to treat autoimmune and inflammatory conditions | CELMED ONCOLOGY (USA), INC. (CA) | 2006-11-21 | — | — | US | disclosed |
| EP-1359921-A4 | METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS | NEWBIOTICS INC (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20040077588-A1 | Enzyme catalyzed therapeutic compounds | CELMED ONCOLOGY (USA), INC. (CA) | 2004-04-22 | — | — | US | disclosed |
| US-6683061-B1 | 1-(2,3-DIHYDROXYTETRAHYDROFURAN-5-YL)-5-(4-BROMO-1,3-BUTADIENYL) -PYRIMIDINE-2,4(1H,3H)-DIONE; ANTIPROLIFERATION AGENT | NEWBIOTICS, INC. | 2004-01-27 | — | — | US | disclosed |
| EP-1359921-A2 | METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS | NewBiotics, Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030109697-A1 | Novel phosphoramidate compounds and methods of use | KIADIS PHARMA INTELLECTUAL PROPERTY B.V. (NL) | 2003-06-12 | — | — | US | disclosed |
| US-20020151519-A1 | Methods to treat autoimmune and inflammatory conditions | CELMED ONCOLOGY (USA), INC. (CA) | 2002-10-17 | — | — | US | disclosed |
| US-20020147175-A1 | Synergistic ECTA compositions | NEWBIOTICS, INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002056832-A2 | METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS | NEWBIOTICS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002039952-A2 | SYNERGISTIC ECTA COMPOSITIONS | NEWBIOTICS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1202749-A2 | ENZYME CATALYZED ANTI-INFECTIVE THERAPEUTIC AGENTS | Newbiotics, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1200455-A1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | Newbiotics Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001007087-A2 | ENZYME CATALYZED ANTI-INFECTIVE THERAPEUTIC AGENTS | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007454-A1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |